NCT04603027

A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 249 (actual)
• Sponsor: Evelo Biosciences, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.

Detailed description

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-cohort, dose-ranging study of participants with mild to moderate plaque psoriasis. This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.

Conditions

• Psoriasis
• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	EDP1815	EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
DRUG	Placebo	Placebo oral capsule

Timeline

• Start date: 2020-09-21
• Primary completion: 2021-07-02
• Completion: 2021-12-06
• First posted: 2020-10-26
• Last updated: 2022-12-19
• Results posted: 2022-12-19

Locations

29 sites across 4 countries: United States, Hungary, Poland, United Kingdom

Regulatory

• FDA-regulated drug study